搜索
 > 【Syndecan-1】重组蛋白信息

Syndecan-1信息

英文名称:Syndecan-1
中文名称:多配体蛋白聚糖-1
靶点别称:SYND1,CD138,SDC,SDC1
上市药物数量:0
临床药物数量:3
最高研发阶段:临床二期

Syndecan-1 Molecule Synonym Name

SDC1,Syndecan-1,CD138,SYND1,SDC

Syndecan-1 分子背景

Syndecan-1 (SYND1 or SDC1) is also known as CD antigen CD138, is a transmembrane (type I) heparan sulfate proteoglycan and is a member of the syndecan proteoglycan family. The syndecans mediate cell binding, cell signaling, and cytoskeletal organization and syndecan receptors are required for internalization of the HIV-1 tat protein. The syndecan-1 / SDC1 protein functions as an integral membrane protein and participates in cell proliferation, cell migration and cell-matrix interactions via its receptor for extracellular matrix proteins. It is a useful marker for plasma cells, but only if the cells tested are already known to be derived from blood.

Syndecan-1 参考文献

Syndecan-1临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
ATLCAR.CD138 (UNC Lineberger Comprehensive Cancer Center) 临床一期 UNC Lineberger Comprehensive Cancer Center 多发性骨髓瘤, 免疫性疾病 详情
CART-138 (Chinese PLA General Hospital) 临床二期 中国人民解放军总医院 多发性骨髓瘤
Indatuximab ravtansine BT-062; nBT-062 临床二期 Biotest 乳腺癌, 多发性骨髓瘤, 膀胱癌 详情

消息提示

请输入您的联系方式,再点击提交!

确定